• December 5, 2023

NeuroSense’s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Read More

• November 6, 2023

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Read More

• October 4, 2023

NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

Read More

• September 20, 2023

European Medicines Agency Grants NeuroSense SME Status

Read More

• September 19, 2023

NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC

Read More

• September 6, 2023

NeuroSense to Host Investor Webinar on September 12, 2023

Read More

• August 16, 2023

NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

Read More

• July 11, 2023

NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit

Read More

• July 6, 2023

NeuroSense CEO Provides Q2 2023 Update

Read More

• June 22, 2023

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Read More

• May 15, 2023

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

Read More

• May 2, 2023

NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson’s Biomarker Study

Read More

• March 27, 2023

NeuroSense Therapeutics & Massachusetts General Hospital’s NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

Read More

• March 23, 2023

NeuroSense to Present at the ALS and Alzheimer’s Disease at AD/PD™ 2023 Advances in Science & Therapy Conference

Read More

• March 22, 2023

NeuroSense Announces Year End 2022 Financial Results and Provides Business Update

Read More

• March 16, 2023

NeuroSense Therapeutics to Participate in BIO-Europe Spring

Read More

• February 9, 2023

NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases

Read More

• February 8, 2023

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

Read More

• January 19, 2023

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer’s Biomarker Study

Read More

• November 16, 2022

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

Read More